dbo:abstract
|
- Thymoglobulin (manufactured by Sanofi) is an anti-human thymocyte immunoglobulin preparation made of purified polyclonal antibodies derived from rabbits. While these antibodies have a variety of specificities, their main mechanism of immunosuppression is through depletion of T cells. Thymoglobulin is currently approved for clinical use in Europe and the United States for renal allograft rejection, prevention of graft-vs.-host disease, and conditions involving bone marrow failure, including aplastic anemia and has additional off-label uses. (en)
- 抗ヒト胸腺細胞ウサギ免疫グロブリン(こうヒトきょうせんさいぼうウサギめんえきグロブリン)とは、ウサギの抗ヒト胸腺細胞グロブリン(ATG)製剤である。再生不良性貧血の治療や臓器移植後の拒絶反応の抑制(ステロイド剤の効果が不充分な場合等)に用いられる。日本においてはサノフィ株式会社がサイモグロブリンとして販売を行っている。 (ja)
|
dbo:wikiPageID
| |
dbo:wikiPageLength
|
- 6448 (xsd:nonNegativeInteger)
|
dbo:wikiPageRevisionID
| |
dbo:wikiPageWikiLink
| |
dbp:wikiPageUsesTemplate
| |
dcterms:subject
| |
gold:hypernym
| |
rdf:type
| |
rdfs:comment
|
- Thymoglobulin (manufactured by Sanofi) is an anti-human thymocyte immunoglobulin preparation made of purified polyclonal antibodies derived from rabbits. While these antibodies have a variety of specificities, their main mechanism of immunosuppression is through depletion of T cells. Thymoglobulin is currently approved for clinical use in Europe and the United States for renal allograft rejection, prevention of graft-vs.-host disease, and conditions involving bone marrow failure, including aplastic anemia and has additional off-label uses. (en)
- 抗ヒト胸腺細胞ウサギ免疫グロブリン(こうヒトきょうせんさいぼうウサギめんえきグロブリン)とは、ウサギの抗ヒト胸腺細胞グロブリン(ATG)製剤である。再生不良性貧血の治療や臓器移植後の拒絶反応の抑制(ステロイド剤の効果が不充分な場合等)に用いられる。日本においてはサノフィ株式会社がサイモグロブリンとして販売を行っている。 (ja)
|
rdfs:label
|
- 抗ヒト胸腺細胞ウサギ免疫グロブリン (ja)
- Thymoglobulin (en)
|
owl:differentFrom
| |
owl:sameAs
| |
prov:wasDerivedFrom
| |
foaf:isPrimaryTopicOf
| |
is dbo:wikiPageRedirects
of | |
is dbo:wikiPageWikiLink
of | |
is foaf:primaryTopic
of | |